Atyr Pharma在击败Q1收入估计数后,获得“买家”评级,目标价格很高。 Atyr Pharma receives a "buy" rating with a high target price after beating Q1 earnings estimates.

HC Wainwright给予Atyr Pharma“买”评级,目标为35美元,而MocketBeat的平均目标为18.60美元。 HC Wainwright gave Atyr Pharma a "buy" rating with a $35 target, while MarketBeat's average target is $18.60. Atyr Pharma的库存为3.99美元,在52周的1.42至4.66美元之间开放。 Atyr Pharma's stock opened at $3.99, within a 52-week range of $1.42 to $4.66. 该公司击败了Q1收入估计数,报告EPS为0.18美元,而共识为0.23美元。 The company beat Q1 earnings estimates, reporting an EPS of ($0.18) compared to a consensus of ($0.23). Atyr Pharma重点开发基于新生物途径的药物。 Atyr Pharma focuses on developing medicines based on novel biological pathways.